Facebook
X
LinkedIn
ForwardNCCN Webinar Series - Optimizing Patient Outcomes: Collaborative Perspectives in Oncology
The rapid integration of new therapeutic agents into treatment for various types of cancer can be challenging for clinicians. Cancer treatment is constantly evolving, and it is crucial for health care professionals to stay up to date with the latest developments in the field. Pharmacists are critical to the education of the interprofessional oncology care team about the actions and potential adverse events associated with new and existing therapeutic options, as well as patient safety and education, quality of care, and subsequent monitoring and management of treatment-related toxicities.
The NCCN 2026 Webinar Series - Optimizing Patient Outcomes: Collaborative Perspectives in Oncology, facilitated by oncology pharmacists, will provide the interprofessional oncology care team with up-to-date knowledge and skills related to the treatment and management of patients with cancer and highlight the importance of interprofessional care and collaboration between health care providers to ensure the best possible outcomes for patients with cancer.
Target Audience
This program is designed to meet the educational needs of physicians, nurses, nurse practitioners, pharmacists, physician associates and other health care professionals who treat patients with cancer.
Learning Objectives
Following this activity series, participants should be able to:
- Apply current standards of oncology care and NCCN Clinical Practice Guidelines in Oncology to inform evidence-based treatment decisions across a range of cancer types and clinical scenarios.
- Evaluate and integrate novel, emerging, and recently approved therapeutic agents, including targeted therapies, immunotherapies, and other innovative modalities into individualized patient management strategies.
- Enhance interprofessional communication and collaboration to improve coordination, shared decision-making, and overall performance of the oncology care team in delivering optimal patient outcomes.
In a Blink of an Eye: Updates in Frontline Therapy with Blinatumomab for Pediatric Acute Lymphoblastic Leukemia
Wednesday, April 22, 2026 • 12:00 – 1:00 PM EDT
Fallon Henkel, PharmD, BCOP, Yale Cancer Center/Smilow Cancer Hospital
When Prognosis Changes from Good to Poor: Treatment Options for Richter Transformation of Chronic Lymphocytic Leukemia
Wednesday, May 6, 2026 • 3:00 – 4:00 PM EDT
Molly Graveno, PharmD, BCOP, Huntsman Cancer Institute at the University of Utah
WEBINAR TIMES ARE EASTERN DAYLIGHT TIME (EDT) (UTC/GMT -4:00) OR EASTERN STANDARD TIME (EST) (UTC/GMT -5:00).
Access to participate in selected sessions is through Zoom on the day of each scheduled program.
Recordings from the NCCN 2025 Optimizing Patient Outcomes series can be found here.
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Full disclosure of faculty relationships will be made prior to the activity.
This program has been approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, physician associates, and other health care professionals. Complete accreditation information is provided before each individual educational activity.
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing